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Abstract 
Little is known about the relative importance of different causes of death in driving the 
evolution of senescence and longevity across species. Here we argue that cause-specific 
mortality may be shaped by physiological trade-offs between mortality components, 
challenging the theoretical view that physiologically independent processes should senesce at 
the same rate, or that interactions between causes of death will make selection blind to the 
effects of specific causes of death. We review the evidence that risk of cancers trades off with 
risks of mortality from other diseases, and investigate whether this might explain two of the 
most puzzling paradoxes in cancer evolution. First, among species, cancer prevalence is not a 
function of species’ size and longevity, despite the fact that cancer incidence is known to be a 
function of the number of cell divisions (and therefore of size) by unit of time (and therefore 
of longevity). Second, within species, despite the fact that genomic instability is thought to be 
the proximal cause of both cancer incidence and senescence, mortality rates rise with age 
while cancer incidence decelerates and declines at old ages. Building on a relatively novel 
theory from cellular biology, we construct a preliminary model to reveal the degree to which 
accumulation of senescent cells with age could explain this latter paradox. Diverting damaged 
stem cells towards a senescent-state reduces their risk of becoming tumorous; however, 
conversely, the accumulation of senescent cells in tissues compromises their rejuvenation 
capacity and functioning, leading to organismal senescence. Accumulation of senescent cells 
with age may then be optimal because it reduces cancer mortality at the cost of faster 
senescence from other causes. Evolution will drive species towards a balance between these 
two sources of mortality.   
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Introduction 
For any organism, all fitness components cannot be maximized simultaneously. The result 
would be a so-called ’Darwinian demon’ (e.g., a species with both large survival and fertility, 
(Law 1979)); which is improbable based on observations across species, and impossible based 
on logical considerations. Indeed, individuals are constrained by limited resources, which must 
be allocated to different functions of the organism at different times during the organism’s 
life. The result is trade-offs across fitness components. Classic trade-offs in life history 
evolution include investment in current reproduction to the detriment of future survival or 
reproduction (the costs of reproduction, (Williams 1966)), investment in fast growth during 
juvenile life to the detriment of adult fitness, or investment in the production of many 
offspring to the detriment of their survival (the quantity-quality trade-off, (Lack 1947)). An 
alternative trade-off would be investment in a biological function linked to better surviving 
one cause of death, to the detriment of survival of another cause of death. Surprisingly, this 
is rarely considered. 
Our aim here is to explore this question: does mortality components (potentially translating 
to specific causes of death) trade with each other? We start by briefly summarizing the 
evidence for individual level trade-offs between mortality components, a requisite for 
allowing the evolution of varied strategies among species. We also critically review two major 
predictions that may have curtailed research into evolution associated with trade-offs 
between mortality components. We then narrow our focus to one of the most puzzling 
mortality patterns in evolutionary biology: cancer mortality defies prediction both within and 
between species. First, comparing between species, since genomic instability with age is 
thought to be an important proximal cause of senescence, and is known to be the key 
proximate driver of cancer, cancer mortality is expected to map closely to a species’ actuarial 
senescence, and thus longevity. That this is not the case and is known as Peto’s paradox 
(Nunney 1999): cancer prevalence does not correlate with a species’ size and longevity, 
suggesting that cancers are not ‘only’ a by-product of senescence across species. Moving from 
comparison between species to comparisons within species, in humans, as in rats, incidence 
of cancer decelerates and even declines at older ages (reviewed below and in (Anisimov, et al. 
2005)), decoupling cancer from senescence in these species. This lack of association of 
prevalence of cancer with longevity across species and senescence rates with cancer incidence 
by age within species suggests that the molecular and physiological mechanisms underlying 
cancer may be different or at least act differently on morbidity from those underlying other 
causes. Evolutionary theory is thus urgently needed to shed light on how cancer development 
at the level of organisms and species evolved together with lifespan and life-history (Casás-
Selves and Degregori 2011). This is true even when species cancer prevalence is low in the 
wild ((or large only due to recent human-driven changes, Hochberg and Noble 2017)) because, 
in most species, especially the large and the long lived, the puzzling question is how “the 
development and architecture of our tissues were evolutionarily constrained by the need to 
limit cancer” (Casás-Selves and Degregori 2011, DeGregori 2011).  
Recent evidence for a negative correlation between cancer prevalence and that of other 
diseases further emphasizes the disconnection between cancer and other causes of mortality. 
Applying a competing risks model to data on underlying and secondary causes of death in the 
U.S. during 1968–2004, Yashin and colleagues (Yashin, et al. 2009) estimate a negative 
correlation between cancer and asthma (about -2.5%), Parkinson disease (ranging between -
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3 to -5%), Alzheimer’s disease (ranging from -1 to -10%),  diabetes (about -10%), 
cerebrovascular accidents (about -12%) and coronary heart disease (ranging from -25 to -15%). 
These intriguing negative patterns have been shown to also hold in the more finely resolved 
data from the Framingham Heart Study (Ukraintseva, et al. 2010). Importantly, negative 
correlations can emerge from mechanisms other than the physiological trade-offs required to 
drive evolutionary processes. However, molecular and cellular physiologists have several 
hypotheses of mechanisms that could drive these negative correlations (Ukraintseva, et al. 
2010). Among them, the accumulation of cells in senescent-state in tissue may be the 
physiological mechanism mediating negative correlations between mortality by cancers and 
from other causes, by impeding cell divisions and progress towards cancer. Despite its 
potential to illuminate patterns of cancer mortality both within and among species by 
capturing trade-offs between mortality components, this senescent-cells theory of ageing, has 
not formally been previously modeled. 
In this chapter, after summarizing the general question of the potential for trade-offs between 
mortality components, and reasons for their relative neglect in life history evolution studies, 
we detail the core paradoxes around cancer mortality in the context of life history evolution. 
We then introduce a simple preliminary model of the optimization of the dynamics of non-
senescent, tumorous and senescent cells built around the senescent cells theory of ageing and 
discuss implications for evolutionary outcomes related to cancer mortality. This model aims 
to be a ‘proof of principle’ for two main concepts: first, trade-offs between mortality 
components may induce an increase of mortality by age that nevertheless reflects an optimal 
strategy emerging from balancing trade-offs between two different risks of death and; second, 
the senescent cells theory of ageing may be a mechanism that underpins such a trade-off. We 
conclude by discussing how this physiological framing of a trade-off between mortality 
components might resolve paradoxes relating to patterns of cancer prevalence among 
species, and patterns of cancer incidence across age within species. We place this discussion 
within the context of existing theory on aging, and point to methodological approaches that 
could open the way to further investigation of trade-offs between mortality components.  
Potential for trade-offs between mortality components into life-
history theory. 
To survive, an organism must invest considerable energy into maintenance, which 
encompasses many different physiological functions; from higher physiological functions 
(breathing, digesting, maintaining homeostasis, cardiac and neural activities, maintaining the 
immune system and performing immune responses, etc.) to molecular and cellular functions 
(controlling and repairing DNA, maintaining proteostasis and cellular metabolism, etc.). 
Although these functions are tightly interconnected physiologically, they nevertheless depend 
on specific genetic architectures that do not completely overlap. For instance, genes involved 
in immunity differ from those controlling cell replication and tumor suppression. Categorizing 
genes according to their functions (or phenotypes) is one of the most intense current research 
focuses of molecular biologists. Construction of vast databases reporting action of genes at a 
higher integrative level (e.g., Polymorphism Phenotyping v2) is underway. A crucial focus of 
this effort is to link these emergent functions or phenotypes to the vast epidemiological 
genetic literature on diseases resulting from polymorphisms at underlying genes. This effort 
has yielded increasing evidence for so called ‘antagonistic pleiotropic’ effects of gene(s), 
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meaning effects which are positive for one fitness component, but negative for another. In 
particular, evidence for genetic trade-offs between mortality components has emerged. The 
most famous example is polymorphisms in APOE-ε4, a gene involved in many 
neurodegenerative syndromes in adults but that allows higher levels of vitamin D absorption, 
and for instance protects children against diarrhea (reviewed in (Oriá, et al. 2007)). There are 
therefore multiple lines of evidence supporting the existence of genetic level trade-offs 
between mortality components. 
But do these potential trade-offs, detectable in the impacts of a single gene, translate into 
unavoidable physiological trade-offs, reflecting differential allocation of resources between 
physiological functions linked to survival, thus of importance for life history evolution? To our 
knowledge, this has never been formally evaluated, and the mapping between evidence for 
antagonistic pleiotropy and physiological tradeoffs is likely to be complex. Nevertheless, 
striking gradients across species in investment in survival-related functions suggest that 
physiological, resource allocation based trade-offs are likely. For example, investment in 
immune system function, a key line of defense against pathogens, and thus important for 
individual survival, is highly variable across species (reviewed in (Schmid-Hempel 2003)). 
Digestive organs consume a significant fraction of metabolic energy (20-25% in vertebrates, 
reviewed in (Karasov and Douglas 2013)), but this varies considerably among species 
according to the biochemistry of food intake. Intriguingly, the surface of the intestine is also 
the major contact zone between the immune system and food-borne and microbial antigens, 
making interactions and trade-offs between digestive and immune systems crucial in 
ecophysiology (Meitern, et al. 2016). Similarly, the brain is an extremely energy consuming 
organ which demands high levels of maintenance. Yet brain size varies substantially across 
species and correlates positively with basal metabolic rate in mammals (Isler and van Schaik 
2006). Given these striking life history gradients across species, one might therefore wonder 
why trade-offs between underlying mortality components (and associated physiological 
functions) have been little incorporated into evolutionary demography and life-history theory. 
Two theoretical predictions may have been responsible for curtailing research in this direction. 
First, in George Christopher Williams’ seminal article on the evolution of senescence, it is 
predicted that:  “senescence should always be a generalized deterioration, and never due 
largely to changes in a single system” (Williams 1957). The idea, reframed by John Maynard-
Smith (Smith 1962), is that all physiologically independent processes should senesce at the 
same rate as “natural selection will always be in greatest opposition to the decline of the most 
senescence-prone system” (Williams 1957). We illustrate this principle in Figure 1 showing 
three Gompertz-shaped distributions of deaths by age and by cause. The observed density of 
deaths from c1 (red polygon) is much larger than densities of deaths from c2 and c3 (green and 
blue polygons) because few individuals survive until ages where c2 and c3 are most likely. This 
shows that selection pressure on susceptibility alleles to a specific cause of death is affected 
by the age-specific risk of other causes of death to which the population is exposed. For 
example, removing c1 from the population will drastically increase the strength of negative 
selection on c2. More generally, gradients of selection occur not only across age, but also 
emerge as a result of other causes of death. For example, assume that the spectrum of 
susceptibility alleles to c2 is at a mutation-selection balance, and selection is just above the 
threshold at which it can overcome genetic drift. As a result, negative selection is weak but 
will eventually purge deleterious mutations associated with c2. All else being equal, 
susceptibility alleles to c1 will be more intensely negatively selected. Purifying selection will 
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thus decrease the number and the frequency of c1 alleles, eventually decreasing the frequency 
of deaths from c1. By contrast, susceptibility mutations to c3 are neutral and mutations will 
accumulate, eventually increasing the frequency of death from c3. Overtime, therefore, 
natural selection will tend to homogenise the rate at which cause-specific mortality increases 
with age. 
The validly of this hypothesis has been extensively discussed, and empirical evidence for 
challenges to it reviewed (Gaillard and Lemaître 2017). Several studies show that 
demographic, phenotypic and functional traits do not senesce synchronously (e.g., in Soay 
sheep in (Hayward, et al. 2015) or in reptiles in (Massot, et al. 2011)). However, this lack of 
synchronicity in rates of senescence among different functions is, as yet, largely unexplained. 
As shown in figure 2.B (solid line) trade-offs between mortality components may provide part 
of the answer.  
 
Figure 1 - Stacked distributions of deaths          1 2 3c cf t S t S t S t h t  across age t for three 
causes of death c1, c2 and c3 (red, green and blue polygons, respectively); the corresponding 
overall survival over age        1 2 3S t S t S t S t  (grey polygon and right axis); as well as the 
distribution of death from each cause      c c cf t S t h t  in the case where individuals die from 
only this cause (red, green, and blue dotted lines). In this example, cause-specific mortality 
hazards are Gompertz-shaped (such that ( ) c
b t
h t ae , with a=0.001, b1=0.1, b2=0.07 and 
b3=0.05). 
The second theoretical feature that may have reduced research into the question of trade-
offs between causes of death is the lack of independence among causes of death: 
multiplicative effects are likely to be ubiquitous. For example, inflammation underlies multiple 
causes of death, from heart disease to cancer (Coussens and Werb 2002, Willerson and Ridker 
2004). This major concept in epidemiology also raises inferential difficulties in characterizing 
causes of death. Many causes likely contribute to each death, particularly in older individuals, 
and disentangling their contribution is consequentially statistically challenging, especially as 
each mortality event occurs only once. To disentangle these complex causal pathways, 
epidemiologists distinguish between proximal and distal factors leading to death. This has led 
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researchers to envision senescence as the accelerated accumulation of a health deficit whose 
ultimate outcome, death, whatever its cause, cannot be seen as the result of the deterioration 
of a sole physiological function (Kulminski, et al. 2007, Yashin, et al. 2007). As a consequence, 
selection on allocation strategies between mortality components at an evolutionary scale 
might be obscured by covariation between causes of death at the individual scale.  
However, to our knowledge, this has not been formally framed, and we explore this in Figure 
2. Extending the model presented in Fig. 1, we assume this time that the third cause of death 
is the result of an interaction between mortality components respectively responsible for 
causes of death 1 and 2. This model captures the fact that, over the course of an individual’s 
life, factors that increase the risk of cause of death c1 may also have the effect of increasing c2 
and vice versa. Figure 2A show the distribution by age and causes in the scenario where 25% 
of deaths result from these interactions. Assuming that cause-specific senescence rates result 
from an allocation strategy in the maintenance of the respective physiological components, 
we illustrate in figure 2B that an allocation strategy optimizing life-expectancy can still be 
identified in the case where causes of death (c1 and c2) covary, such that the cause of death is 
indistinguishable in 25% of cases. This scenario flattens the optimal allocation balance 
between the two biological functions relative to the case where both are fully independent 
(Figure 2B, solid line), but an intermediate optimum can still be identified (Figure 2B, dashed 
line).  
 
 
 
Figure 2 - As for figure 1, but in the case where causes of death are not independent. Cause c3 
is now the product of the interaction c1xc2 between c1 and c2 such that    1 221x2
b b t
h t za e

  
(where z  is the coefficient of this interaction, b1 is a parameter shaping the hazard associated 
with cause c1, and likewise for b2). Panel (A) shows the distribution of deaths in this case 
(taking z=35 such that c1xc2 accounts for more than 25% of observed deaths). Panel (B) further 
assume a stationary population of a species whose fertility rates are constant over age, such 
that remaining life expectancy e  at age α is an adequate measure of adult fitness. We assume 
a linear negative relationship between b1 and b2 that captures a trade-off between causes of 
death. The remaining life expectancy e  is then depicted for a range of parameters  1 2,b b  in 
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the case where z=0 (no interaction between causes of death, solid line) and in the case where 
z=35, dashed line).  
Cancers and physiological ageing 
Ageing is multifactorial. In their seminal review (Lopez-Otin, et al. 2013), Carlos López-Otín 
and colleagues described nine mechanisms leading to functional deterioration with age. Core 
aspects of deterioration have been usefully categorized as primary causes of intracellular 
damage (genomic instability, telomere attrition, epigenetic alteration and loss of 
proteostasis), cellular dysfunction (deregulated nutrient sensing, mitochondrial dysfunction, 
and cellular senescence) and altered tissue dynamics (stem cells exhaustion, altered 
intercellular communication). To incorporate these proximal functional deteriorations into an 
evolutionary demographic framework for understanding ageing requires understanding to 
what extent each is linked to mortality in general, and to specific causes of death in particular.    
Cancers may be the pathology for which this link is the most straightforward. All cancers 
appear to be genetic diseases at the cellular level. The current dominant theory of a cell 
carcinogenesis (but see below) is a multistage process requiring the accumulation of 
(epi)mutations in a mitotic cell lineage (often called ‘hits’), ranging up to large chromosomal 
abnormalities and aneuploidy. The outcome is liberation of neoplastic cells from homeostatic 
mechanisms of cell division, potentially resulting in development of cancer. This multistage 
theory of carcinogenesis was first proposed in the fifties by Peter Armitage and Richard Doll 
(Armitage and Doll 1954) and mathematically formalized in its most frequently used 
expression by Richard Peto (Peto 1977). However, the underlying multistage genetic processes 
required to generate the series of 6 to 8 ‘hallmarks’ of cellular physiology that transform a 
normal cell to a neoplastic cell have only recently been characterized (reviewed in Hanahan 
and Weinberg 2011). The number of ‘hits’ required for carcinogenesis varies from two 
(Knudson 1971) to eight (Vogelstein, et al. 2013) as a complex - and yet unknown - interactions 
between species, tissues and cancer types (Nunney and Muir 2015). Quantifying the rate of 
accumulation of somatic mutations with age (due to increased mutation rate and decreased 
repair efficiency) and amongst species; for example using transgenic LacZ animals (reviewed 
in Moskalev, et al. 2013) is therefore fundamental to characterizing the links between 
proximal somatic mutation accumulation to distal cancer morbidity.  
Importantly, despite the detailed mechanisms proposed to explain carcinogenesis, the 
functional relationship between mutation accumulation in stem cells lineages and cancer risk 
remains poorly described. It has been shown recently that lifetime risk of cancer correlates 
with total number of cell divisions in tissues (Tomasetti, et al. 2017, Tomasetti and Vogelstein 
2015), but the kinetics of damage accumulation with age, and how this shapes cancer 
incidence is still little known and intensively debated. As recently pointed out, about 50% of 
stem cell somatic mutations occur during ontogenesis; and this mutation accumulation does 
not translate into increases in cancer at that life stage. By contrast, cell divisions slow down 
during adult life, yet this does translate into an exponential increase in cancer incidence 
(Rozhok and DeGregori 2016). The Doll-Armitage multistage model is therefore not sufficient 
to explain cancer incidence by age and alternative evolutionary-based hypotheses have been 
proposed (DeGregori 2017). 
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Telomere inhibited-attrition is also linked to risk of cancer. In normal cells, telomerase 
inhibition and telomere shortening limits the number of cell divisions, a phenomenon denoted 
as ‘the Hayflick limit’(Hayflick and Moorhead 1961), corresponding for example to under 50-
70 divisions in fibroblasts. Once this limit is reached, cells enter a so-called ‘senescent’ state 
and stop replicating. In most human cancers, telomerase activation past this limit impedes 
telomere attrition and confers cell immortality (Donate and Blasco 2011, Shay and Bacchetti 
1997). The role of epi-mutations in carcinogenesis is also increasingly studied. Recently, a 
strong correlation between chronological and epigenetic age has been identified, accounting 
for tissues and cells type (Horvath 2013). Epi-mutations – mutations leading to abnormal 
repression or activation of genes – have been proved to be a frequent proximate mutational 
event leading to carcinogenesis (Banno, et al. 2012).  
Risk of cancers is also linked to cellular dynamics. Carcinogenesis can indeed be framed as the 
result of a dynamical interplay between predation by the immune system, and competition 
between cancer and normal cell lineages in a changing fitness landscape (Rozhok and 
DeGregori 2016) , with a pinch of stochastic drift (Crespi and Summers 2005, Pepper, et al. 
2009, Shpak and Lu 2016). This “ecological theater of carcinogenesis” (Crespi and Summers 
2005) also changes through age, in ways expected to make cancer occurrence more likely. For 
example, hematopoietic stem cell exhaustion resulting from other ageing processes (such as 
increased genetic instability due to accumulation of oxidative damage (Ito, et al. 2004)) leads 
to a decline of the production of adaptive immune cells with age (a process called 
immunoscenescence) and therefore reduces the organisms ability to keep cancerous cell 
lineages in check (reviewed in Henry, et al. 2011).  
Overall, and although alternative theories are emerging (DeGregori 2017), (epi)genetic 
instability leading to mutation accumulation in stem cell lineages is still considered the primary 
factor  required for cancer development at the cellular level; and prevention of telomere 
attrition the most common way for cancer cells to escape replication homeostasis. 
Accumulation of mutations with age should therefore correlate with increased cancer 
incidence. Importantly, these drivers are the very same as those invoked for senescence at 
the individual level. However, this link is paradoxical at two levels: between and within 
species.  
Prevalence of cancers across species and Peto’s paradox 
Cancers are ubiquitous in multicellular organisms and occur each time that a cheating cell 
escapes the bounds defining cooperation among cells by escaping inhibition of proliferation 
and cellular death (Aktipis, et al. 2015). Data on the prevalence of cancers across the tree of 
life are scarce and the ecological, physiological and phylogenetic determinants of a species 
cancer prevalence are mostly unknown (see below). However, preliminary results (based on 
limited data) tend to confirm one of the most puzzling paradoxes of evolutionary biology 
(Abegglen, et al. 2015): the fact that cancer prevalence is not a function of organism size or 
longevity.  
The fact that this is paradoxical was first pointed out by Sir Richard Peto (Peto 1977): in a 
multistage carcinogenesis process, accumulation of damage within cells’ lineages should be a 
function of the number of cell divisions, itself a function of the number of cells and lifespan. 
However, while mice are 1000 times smaller and about 30 times shorter lived than humans, 
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cancer incidence is about the same (Rangarajan and Weinberg 2003). This led Peto to ask 
whether our stem cells are “a billion or a trillion times more "cancerproof" than murine stem 
cells?” and “Why don't we all die of multiple carcinomas at an early age?” (Peto 1977, pp 1413-
1414). Nunney (1999) first denoted this ‘Peto’s paradox’; and explored the issue via a 
population genetic model where cancer incidence depends on the number of ‘hits’ required 
for a given cell to turn into cancer. This model demonstrated that highly proliferating tissues 
require additional controls of carcinogenesis as organism size increases to prevent cancer 
prevalence from wiping out the entire species (Nunney and Muir 2015).  
 
The degree to which Peto’s paradox holds across taxa remains however largely unresolved. To 
date the most extensive comparative study of cancer incidence with body mass and lifespan 
included only 31 mammal species; and cancer incidence estimates for a subset of these 
species were based on only 10 necropsies (Abegglen, et al. 2015). Both richer data, but also 
more complete statistical analyses are required to answer this question. The latter is 
necessary because, first, while multistage carcinogenesis theory predicts that longevity should 
be positively correlated with cancer prevalence; cancer morbidity is obviously negatively 
correlated to longevity and comparative studies should account for this. Second, longevity 
emerges from both a species’ magnitude of intrinsic mortality per unit of time (e.g, the a 
parameter of a Gompertz-shaped mortality, or the intercept of the log mortality function) but 
also the rate at which mortality rises with age (e.g., the b parameter of a Gompertz-shaped 
mortality, or the slope of the log mortality function). Each, both or neither might be associated 
with cancer incidence and thus inform the generality of Peto’s paradox. Overall, age-specific 
data are urgently needed in comparative oncology to assess the role played by cancer in 
ageing.  
Furthermore, cancer prevalence does vary between species beyond the effect of size. A recent 
review of cancer prevalence and etiology in wild and captive animal populations (Madsen, et 
al. 2017) revealed that prevalence in wild vertebrates ranges from 0.2% to more than 50%. 
Two striking conclusions emerged from this review. First, in some species, cancers are one of 
the most prevalent current causes of death in nature, making them an important fitness 
components, and therefore, of crucial ecological and evolutionary significance (McAloose and 
Newton 2009, Vittecoq, et al. 2013)  (although one should note that the extent to which the 
documented cancer risks emerge from recent environmental conditions is still unclear 
(Hochberg and Noble 2017)). Second, cancer prevalence depends less on species’ size and life 
expectancy and more on phylogeny (e.g., reptiles seem more sensitive to cancer than 
mammals) or ecology (e.g., small carnivores exhibit larger average prevalence of cancer than 
large herbivores). Further, despite some such broad patterns, most of the time, species 
specific cancer prevalence defies prediction (e.g. one of the larger prevalences of cancer, 
about 50%, is observed in a large herbivorous mammal, the Cape mountain zebra, but this 
results from a particular case of equine skin cancer (Marais and Page 2011)). In domestic dogs, 
large dogs have larger rates of cancers than small dogs (Fleming, et al. 2011). This is likely due 
to artificial selection on size, which has also resulted in the fact that life expectancy of large 
dogs is lower than that of small dogs (Kraus, et al. 2013) and which makes dogs an outlier 
relative to the usual pattern linking size to lifespan across species, and therefore preventing 
generalization. Other species, such as the naked mole rat, exhibit as yet unexplained low 
cancer incidence (Buffenstein 2008, Taylor, et al. 2017). More generally, rodents are promising 
model species for research on cancer suppression mechanism and its links to ageing 
(Gorbunova, et al. 2014). 
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Despite these heterogeneities, arguably, the broad sweep of available evidence continues to 
align with Peto’s paradox. Many explanations have been proposed to resolve Peto’s paradox 
(reviewed in (Caulin and Maley 2011)). Among others, a lower mutation rate could be efficient 
in limiting carcinogenesis – for example, a three fold decrease in the mutation rate in humans 
compared to mice would be sufficient to lead to similar cancer incidence (Caulin, et al. 2015). 
However, mutation rates have not yet been proved to differ between mice and humans. 
Alternatively, differences in the efficiency of ‘gatekeeper’ tumor suppressor genes - genes 
enforcing checkpoints to suppress neoplastic transformation - could make the number of ‘hits’ 
required for carcinogenesis differ among species. It has been mathematically shown several 
times that increasing the number of ‘hits’ required for neoplastic transformation is a 
particularly efficient approach to preventing cancers in large species (Caulin, et al. 2015, 
Nunney and Muir 2015), but, to date, there is no empirical evidence to support this. For 
example, the number of replicates of tumor suppression genes of the TP family might be 
expected to correlate with species’ size, as this would make tumor suppression more efficient. 
However, this does not seem to be the case overall, although, suggestively, a large number 
copies of TP53 is found in elephant species (Caulin, et al. 2015). Cells’ dynamics (mainly 
influenced by cells’ anatomical compartmentalization, and cells’ effective size, both of which 
affect the stochastic disappearance of cancer cell lineages), immune and apoptotic 
efficiencies, regulation of the number of potential division through telomere length are all 
good hypotheses that should be investigated with respect to the link between size, cancers, 
and phylogeny. The metabolic hypothesis is also receiving increasing support (Caulin and 
Maley 2011, Dang 2015): because the by-products of metabolism (such as reactive oxygen 
species) correlate with metabolic rate, and because basal metabolic rate scales with mass, 
cells may be less exposed to metabolic damages as an animal’s size increases. Finally, an 
aspect that may have received too little attention to date is the role of cell division rate. Caulin 
et al. (2015) demonstrate that a decrease from 1 division every four days to 1 division every 
8-13 days would be enough to account for similar cancer incidence between species differing 
in size by a factor 1000. 
Overall, these various lines of evidence suggest that there is striking gap in life history theory 
around understanding the role of cancers, particularly in the context of Peto’s (as yet 
unresolved) paradox, and associated elucidation of the drivers of cross-species patterns. As 
physiological trade-offs are the clay from which life-history is molded, a key step will be to 
identify which other life-history components are affected by physiology investments that 
reduce cancer incidence.  
The paradox of deceleration and decline of cancer incidence with 
age. 
Close examination of existing research on the topic of cancer incidence reveals another 
striking paradox that has so far been neglected in studies of life history evolution. As 
summarized above, cancer is the cause the death that is the most easily tied to the most 
proximal functional mechanisms of senescence, in particular, the accumulation of damage in 
somatic cells lineages with age due to genomic instability. Cellular dysfunctions also increase 
with age and are linked to increased cancer incidence. Together, these patterns suggest that 
increases in cancer incidence should significantly contribute to, and closely match in shape, 
the increase of mortality with age. Surprisingly and paradoxically, this is not the case. The 
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proportion of deaths due to cancer decreases after age 50-60 years old, mostly to the gain of 
diseases of the circulatory and respiratory systems (see figure 3A and 3B). As a result, cancers 
become the cause of death the least involved in senescence past these ages. A decline in 
cancer mortality rates has even been demonstrated  for very old ages (Smith 1996). The 
general pattern for most cancers in humans is that incidence first increases with age, then 
decelerates and even declines at old ages (see figure 3C). This has been known since the sixties 
(e.g. in (Cook, et al. 1969)) and has since been demonstrated for a large diversity of cancers 
and populations, for example in 2005 France (Bélot, et al. 2008) or in 2012 Korea (see Fig. 3A 
in (Jung, et al. 2015)). Deceleration is even visible for a given population of a given age, at a 
given site, but for different histopathologic subtypes of breast cancers (Anderson, et al. 2006). 
This proves true even when prevalence of cancers differs due to environmental conditions, or 
between the sexes. For example, prevalence of esophageal cancer is much larger in rural than 
in urban China, and in males than in females (Chen, et al. 2014). However a deceleration of 
incidence of cancer past 70 years old, or its decline past age 80 is always observable. It must 
be stressed that deceleration of cancer incidence alone is paradoxical; but the decline in the 
incidence in the oldest old makes it even more puzzling. Yet, recent reviews of the literature 
unambiguously confirm this decline in the oldest old (Harding, et al. 2008, Nolen, et al. 2017, 
Pavlidis, et al. 2012); making cancer one of the least prevalent causes of death in centenarians. 
For example, cancers account for 24.5% of the deaths at 80-84 years old in 2001-2010 England 
and drop down to 4.4% in people surviving 100 years old. Finally, humans are not exceptional 
in this respect. Similar decelerations and declines of cancer incidence with age has also been 
demonstrated in rats (e.g., (Pompei, et al. 2001) and reviewed in (Anisimov, et al. 2005)) and 
in domestic dogs (Fleming, et al. 2011). 
 
 
12 
 
Figure 3 - Stacked crude death rates (A) and proportions of death (B) per causes in France in 
2005. Data were gathered by the 'Centre d’épidémiologie sur les causes médicales de décès' 
de l’Institut national de la santé et de la recherche médical (Inserm-CépiDc). Data, data 
documentation, and methods for death rates calculation can be found here 
http://www.cepidc.inserm.fr/. Panel (C) shows sex-specific incidence and mortality by cancers 
by age in 2005 France. Figure is reproduced from Bélot et al. (2008); where exceptionally 
detailed data on cancer incidence per site can also be found. 
 
Several explanations for deceleration and decline in cancer incidence with age are discussed 
in (Anisimov, et al. 2005, Arbeev, et al. 2005, Hanson, et al. 2015). Detection bias (i.e., resulting 
from the fact that diagnosing cancers is more difficult in the oldest, frailest individuals, 
because many procedures are too invasive) or cohort-period bias (i.e., resulting from the fact 
that oldest cohort may have been less exposed to a cancer-prone environment) can only 
partially explain the results in humans, and are unlikely in other species. Two major 
hypotheses remain. Both were first proposed in studies carried out by A.I. Yashin. The first 
hypothesis is an application to cancer mortality of “the impact of heterogeneity in individual 
frailty on the dynamics of mortality” developed by (Vaupel, et al. 1979). The selective 
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disappearance with age (also called differential selection) of individuals genetically or 
environmentally more susceptible to cancer will mean that the proportion of individuals less 
prone to cancer will increase with age. Change in population structure in oldest age-classes 
may lead to an apparent decline of the aggregated incidence rates (Vaupel and Yashin 1986). 
However, evidence from laboratory animals that display this decline despite low levels of 
genetic and environmental heterogeneity (Anisimov, et al. 2005) suggest that this 
heterogeneity is unlikely to be the sole cause of this pattern. Even in humans, aspects of the 
age profile of mortality suggest that heterogeneity in cancer susceptibility is unlikely to be the 
only factor underlying this pattern. In a frailty model, the inflection of the hazard should be 
maximal when selective disappearance is the highest. In most cases of cancer, this inflection 
occurs at the oldest ages (after age 75-85) while cancer incidence starts rising quickly much 
sooner, at ages around 40-50 (e.g., (Jung, et al. 2015)), suggesting that inflection in incidence 
should occur sooner than observed in most cases (although further investigation is necessary). 
But this may also be because magnitude and typology (individual, familial or social; 
(epi)genetic or environmental; inherited or acquired) of heterogeneity in cancer susceptibility 
is unknown for most cases of cancers. At the end of the day, the role played by heterogeneity 
(among other causes) in shaping cancer incidence has been largely understudied (Hanson, et 
al. 2015).  
A good example of this is breast cancer, perhaps the type of cancer for which genetic 
determinants are the best known. In this case, it is estimated that ‘only’ 5-10% of women with 
breast cancer have a familial history, making selective disappearance of women at higher risk 
of cancer due to genetic susceptibility or shared familial cancerogenous environment likely 
insufficient to explain decline of incidence at old age (Balmain, et al. 2003, Melchor and 
Benítez 2013). For example, in 2000-2005 USA, breast cancer incidence starts declining after 
age 75 years old. This decline is unlikely to be due to the selective disappearance of individuals 
carrying mutations on the two major susceptibility gene to breast and ovarian cancers, BRCA1 
and BRCA2, because recent evidence show that they account only for about 20-25% of the 
familial risk and because 39-65% and 11-39% of carriers would have already developed either 
a breast or ovarian cancer by this age. However the age-specific incidence of numerous 
susceptibility genes of low, moderate and high penetrance, and accounting for about 25% of 
the familial risk, have yet to be investigated (Melchor and Benítez 2013). About 50% of familial 
risk is as yet unknown, and is likely to result from polygenic risk factors, gene-environment 
interactions or shared familial cancerogenous environment. Finally, both the age at which the 
deceleration starts and the age at which the decline in incidence occurs varies widely between 
populations (e.g., between Japan and US (Tsuchida, et al. 2015) or between Asian populations 
(Youlden, et al. 2014)). The range of differences is far too large to result from differences in 
frequencies of genetic susceptibility between populations, emphasizing the role played by 
other types of heterogeneity (beyond the familial or genetic to social or environmental) - in 
shaping breast cancer incidence by age.   
A second set of hypotheses relates to the fact that somatic ageing may slow down incidence 
of cancer with age (Ukraintseva and Yashin 2001, Ukraintseva and Yashin 2003). As introduced 
above, cancer incidence may be linked to metabolic rates, and cell proliferation rates. 
Although humans have been recently proved to have a larger basal (or resting) metabolic rate 
(BMR) than great apes (Pontzer, et al. 2014), this latter declines with age in adults ((Mitchell 
1962); reviewed in (Manini 2010)), and this might thus shape declines in cancer incidence. 
However, the existence of such a decline across species is debated (reviewed, and argued for, 
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in (O'Connor, et al. 2002)) preventing generalizations as to this cause of declines in cancer 
incidence with age across species. Moreover, it is expected that such a decline in metabolic 
and cell proliferation rates would reduce genomic instability and therefore should decelerate 
both cancer incidence and senescence; failing therefore to solve the paradox of the 
deceleration/decline of cancer incidence with age. A related set of hypotheses specifically 
involve trade-offs between cancers and other causes of death (reviewed in (Ukraintseva, et 
al. 2010)). A novel one (not discussed by Yashin and colleagues, and so far rarely considered 
in the literature) is rooted in the role of the accumulation of cells in senescent-state in tissues 
with age. We discuss this in detail in the next section.  
Overall, whether decline in cancer incidence is related to selective disappearance at the 
population level, or molecular or physiological mechanisms occurring at the individual level, 
is a question of fundamental importance for life-history theory. Increases in mortality with age 
have been shown to be erratic in many species (Jones, et al. 2014). Whether this pattern 
occurs because of population levels bias in the estimation of vital rates aggregated at the 
population level (for example resulting in mortality plateaus), or the product of physiological 
mechanisms occurring at the individual level is the subject of intense debate. Resolving this 
debate is likely to require leveraging existing knowledge of physiological mechanisms 
underpinning causes of mortality. As a result, focusing on cancers may provide crucial progress 
towards solving this question. 
Avoiding death by senescence: The senescent-cells theory of ageing 
as a unifying theory? 
In renewing tissues, mitotic cells (i.e., pluripotent stem cells or unipotent progenitor cells) 
divide to produce a specialized cell that assures tissue function, and a mitotic cell that 
maintains the tissue’s rejuvenating capabilities. The mitotic cells’ division is paramount to 
maintaining tissues’ integrity as they age. Tissue stem cells avoid mutations, and excessively 
rapid telomere shortening, by dividing very infrequently (once every 40 weeks for 
hematopoietic stem cells according to (Catlin, et al. 2011)). Still, dividing cells are more at risk 
of accumulating DNA mutations (Moskalev, et al. 2013), and are thus at risk of turning 
neoplastic. This is why the number of cell divisions is limited, a fact first discovered by (Hayflick 
and Moorhead 1961) who showed that in vitro cultivated fibroblasts eventually stop 
replication even when space and nutrients are abundantly provided. Known as the Hayflick 
limit, this is due to the fact that cells enter a life-cycle state known as cellular senescence: “a 
stable arrest of the cell coupled to stereotyped phenotypic changes”  (Lopez-Otin, et al. 2013). 
These phenotypic changes (reviewed in (Campisi and d'Adda di Fagagna 2007, Kuilman, et al. 
2010)) include a permanent growth arrest, mainly in G1 phase, linked to altered gene 
expression, and the secretion of pro-inflammatory molecules. Importantly, they also include 
resistance to apoptosis, meaning that senescent cells ultimately die by necrosis and are 
eliminated by phagocytosis. 
Causes of cellular senescence are reviewed in (Campisi and d'Adda di Fagagna 2007, Collado, 
et al. 2007, Kuilman, et al. 2010, Lopez-Otin, et al. 2013). Most of them are associated with 
mechanisms preventing the replication of cells that have accumulated intracellular damage. 
As such, these mechanisms obviously play a crucial role in preventing cancers. First, telomeres 
shorten at each division. When telomeres become critically short, the p53 tumor suppressor 
protein pathway activates either cellular senescence or apoptosis (although the drivers 
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directing a given cell towards one or the other fate are, as yet, unknown). This limits the 
number of normal cell divisions, and contributes to replicative senescence (Kuilman, et al. 
2010). It may also lead to premature senescence of cells that have initiated neoplasic 
transformations: as discussed above, in most cases of cancers, cells have mutated to higher 
activation of telomerase, and associated telomere length maintenance. Severe DNA damage 
(unrepaired DNA damage and chromosomal damage) can also activate p53 pathways towards 
senescence or apoptosis. Molecular biologists have also identified many pathways (e.g., 
Ras/Raf/MEK) that detect problems in the expression of specific genes which may induce 
cancers (called oncogenes). These pathways then activate the production of two major 
proteins p16INKa and p19AFR (in mice, or p14AFR in humans) which induce cellular senescence.  
While cellular senescence plays a key role in preventing development of cancers, importantly, 
it may also have deleterious effects: accumulation of senescent cells in tissues may alter their 
renewal and function. There is ample evidence that cells in a senescent state do accumulate 
in tissues as individuals age (e.g., (Dimri, et al. 1995) in humans or (Herbig, et al. 2006) in 
baboons, reviewed in (Jeyapalan and Sedivy 2008)); although the kinetics of this accumulation 
over age remains unknown. Moreover, evidence that this accumulation is a cause rather than 
a consequence of ageing has long been largely circumstantial. Recently, the development of a 
technique allowing selective killing of senescent cells in tissues in transgenic mice (Baker, et 
al. 2011) allowed the issue to be resolved. Removal of senescent cells delayed onset of age-
related disorders (Baker, et al. 2011, Ogrodnik, et al. 2017) and even increased lifespan (Baker, 
et al. 2016, Ogrodnik, et al. 2017). Unexpectedly, this procedure also delayed carcinogenesis, 
the opposite of what would have been expected under the ‘senescent cells theory of aging’. 
Possible explanations for this discrepancy include delayed carcinogenesis as a consequence of 
the complicated experimental procedure on transgenic mice lineages used in these studies; 
or potentially non-linear patterns of damage accumulation in stem cells lineages as organisms 
age, under differential replication rates and relative importance of apoptosis and senescent-
state transitions, making the age at which treatment is applied drive potentially different 
outcomes. A final explanation might link this outcome to induction of hyperplasia (often an 
initial stage of cancer) associated with the pro-inflammatory phenotype of senescent cells 
demonstrated in some cases of experimentally induced cellular senescence (Campisi 2013), as 
for instance in the case of genotoxic chemotherapies (Demaria, et al. 2017). 
Overall, recent studies tend to confirm a hypothesis expressed by many molecular and cellular 
biologists: molecular pathways that suppress carcinogenesis (such as the p53–ARF pathway) 
are also involved in apoptosis, and cell entry into a senescent-state (Alderton 2007). As such, 
cellular senescence or telomere shortening are “strategies that protect us from cancer” but 
also “might hasten our rate of ageing” (Finkel, et al. 2007). Accumulation of senescent cells in 
tissues with age could be an adaptive mechanism to prevent cancers, at the cost of a decline 
of tissue function and rejuvenation capacity with age. This maps onto the definition of a 
physiological trade-off in life-history theory, but, strikingly is framed as a trade-off between 
two mortality components: mortality by cancer, and mortality by other causes of death 
underpinning actuarial senescence. Following this logic through using an evolutionary biology 
perspective suggests that senescence could be optimal because it allows reduced cancer 
mortality at early ages, at the cost of increased mortality associated with deterioration of 
physiological function at older ages. It has curiously not yet (to our knowledge) been 
confronted with evolutionary theory of trade-offs and ageing; and even less been 
mathematically modeled.  
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A preliminary model of cellular dynamics with age  
Applying a mathematical model to investigate the implications of this tradeoff is a key step: 
an integrated theory encompassing different forms of mortality may have the power to solve 
both Peto’s paradox and the paradox of the deceleration/decline of cancer incidence with age. 
First, if accumulation of senescent cells with age is optimal, it may lead to non-continuous 
increases of mortality by cancer and senescence with age (investigated below), thus resolving 
the incidence by age paradox. Second, since an accumulation of senescent cells with age is, at 
least partially, a function of the number of replicating cells in a given organism, this sets it in 
line with all hypotheses proposed to solve Peto’s paradox. If senescent cells optimally 
accumulate at different paces within tissues between species of different sizes and longevities, 
large and long-lived species may exhibit increased aging rates that would consequently 
decrease prevalence of cancers. 
To investigate whether the accumulation of senescent cells with age could be optimal, and 
might lead to deceleration and decline of incidence of cancer with age, we develop in Box 1 a 
simple preliminary model of the dynamics of senescent and tumourous cells with age, and 
their effects on cause-specific mortality (see Box 1 for the definition of tumourous cells used 
here).This model incorporates three core attributes describing cellular dynamics, including, 
first, an increased risk that a cell becomes oncogenic as the organism’s age increases (captured 
by the expression x, which increases linearly from 0 to 1 over   time-steps, implying that 
age is ‘biological’, corresponding to the unspecified amount of chronological time required for 
a proportion αx of cells to turn neoplastic); second, a constant probability that tumorous cells 
enter  a senescent state (reflected by the parameter ); and third, a probability that a 
tumorous cell turns neoplastic as a function of the proportion of senescent cells in a focal 
tissue (modulated by a parameter CSr ). Two parameters are further used to translate the 
cellular makeup of an individual into morbidity: OSr  and  OTr  respectively modulate the 
organism’s morbidity as a function of the proportion of senescent and tumorous cells (both 
sources of morbidity are assumed to be increasing concave up functions of their respective 
fractions).  
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Box 1 – A demographic model for senescent and tumorous cells dynamics and their 
consequent effects on organism morbidity. 
We consider a model organism dying only from two causes: cancer or mortality resulting from 
the accumulation of senescent cells in the organism. We denote 
xS  the proportion of 
senescent cells at exact age x , and 
xT  the proportion of tumorous cells of exact age x amongst 
non-senescent cells. Tumorous cells are defined as cells which have accumulated damage, and 
are at risk of turning neoplastic, and thus leading to cancer, but have not done so yet. 
Senescent cells do not further replicate, do not participate in tissue functioning and eventually 
die from necrosis (not formally modeled here). Tumorous cells are cells that have accumulated 
enough unrepaired deleterious mutations (or ‘hits’), yet have not been eliminated by 
apoptosis, putting them at risk of carcinogenesis if they do not enter into a senescent-stage. 
In one time-step, the proportion of new tumorous cells 
x  is defined by: 
     1 1 CS
r
x x x x x xS T S        
,  (0.1) 
where 
x  is the increasing proportion of cells becoming tumorous with age in a tissue 
(modelling a potentially increased genomic instability with age x) where there are no 
senescent cells. This might reflect either an increase of genomic instability with age, a 
decrease in apoptosis efficiency with age, or their interaction – i.e., apoptosis rates increase 
with age and the resulting gaps might allow replication of damaged neighbouring cells, 
allowing them to become oncogenic. The term    1 CS
r
x s x  captures the fact that tumorous 
cells might be more likely to be generated in tissues whose cell functioning is compromised 
by the accumulation of senescent cells; CSr captures cells’ ability to withstand the impact of 
the proportion of senescent cells. The proportions 
xS  and xT  are respectively then given by: 
  1x x x xS S T      , (0.2) 
Where σ is the proportion of tumorous cells entering into senescence, and: 
   1 1x x xT T      , (0.3) 
In each time-step, the probability of surviving mortality via senescence and mortality via 
cancer are defined from 
xS  and xT  such that: 
  1 OS
rs
x xP S  ,  (0.4) 
where OSr is the organism resistance to accumulation of senescent cells for its survival, and: 
    1 1 OT
rc
x x xP T      , (0.5) 
where OTr  is the organism resistance to tumorous cells. 
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With this framework in hand, we numerically identified the optimal value *  that maximizes 
the organism’s life expectancy for a set of parameters  , , ,CS OS OTr r r .  It must be stressed 
that optimality is used here in its loose sense as a proof of principle that, somehow, natural 
selection may have an influence on the evolution of the trait (Orzack and Sober 1994)– here 
entrance in a senescent-state – which may in turn have shaped incidence of cancer by age and 
senescence. 
Optimal σ* is found for a large range of parameter as soon as rOS<rOT. Parameter rCS  has little 
effect on the optimum but controls the pace of the decline in cancer incidence at old age. One 
example that maps closely onto the empirical patterns of mortality we describe above is 
illustrated in Figure 4. The optimal strategy is to accumulate senescent cells at a low rate with 
 * 0,0.1  . As a result, cancer incidence increases rapidly with age then decelerates and 
declines; thus leading to one potential resolution to the paradox of incidence of cancer with 
age.  
 
Figure 4 – Incidence of cancer (red) and probability of death resulting from the accumulation 
of senescent cells (black) for an optimal accumulation of senescent cells by time-step of 
* 0.05   for parameters 500  , 2.5CSr  , 2OSr   and 2.6OTr  . In this case
 0 * 27E   . 
In the example illustrated here (Figure 4), the optimal strategy consists of diverting 5% of 
damaged cells per time step towards the senescent-state. This optimal strategy allows the 
accumulation of damaged cells early in life, leading to an early and rapid increase in cancer 
incidence (red line). In parallel, senescent cells accumulate at a slower pace, such that 
mortality by other causes rises more slowly than cancers (black line). Eventually, however, 
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when ~40% of stem cells are in the senescent-state, cell proliferation becomes sufficiently 
reduced as to considerably decrease the number of new damaged cells per time-step; leading 
to a decline in cancer incidence, thereby preventing cancers from wiping out the entire cohort 
in a few time steps. Beyond this point in time, the increase of new senescent cells per time-
step obviously also slows down. And yet, as the addition of even a small proportion of 
senescent cells considerably compromises tissue functioning, mortality by other causes of 
death continues to rise (black line).  The optimal σ* results therefore from a balance between 
mortality due to cancer early in life and mortality by other causes later in life.  
Discussion 
We have taken the first step towards characterizing the implications for life history evolution 
of the senescent-cell theory of ageing, proposed by molecular and cellular biologists. 
Senescent-cells (i.e. stem cells that have ceased to replicate) accumulate in tissues with age, 
and, according to the theory, this has two implications for individual mortality. First, diverting 
damaged stem cells towards a senescent-state prevents their replication, and thus prevents 
accumulation of more mutations, and the risk of that these cells become neoplastic, ultimately 
resulting in a reduction in the risk of cancer. However, the accumulation of senescent cells in 
tissues compromises their rejuvenation capacity and functioning, and this leads to organismal 
senescence (Alderton 2007). Following this logic through, we suggest that senescence could 
be (at least in part) selected for because accumulation of senescent cells allows reduced 
cancer mortality at early ages, at the cost of increased mortality-associated deterioration of 
physiological function at older ages. Our preliminary model optimizes organism life 
expectancy as a function of the dynamics of non-senescent, tumorous and senescent cells 
within tissues over age, and their respective relationships with mortality from cancer and 
other causes. We show that accumulation of senescent cells with age can be under the 
influence of natural selection leading to a peculiar pattern of cancer age-incidence: an increase 
in early life followed by a deceleration and decline at old ages. 
This novel result might resolve what we refer to as the ‘the incidence by age paradox’ (see 
above). The paradox is that despite the fact that genomic instability is thought to be the 
proximal cause of both cancer incidence and senescence, and accumulation of mutations with 
age leads to an exponential rise of mortality by many causes, cancers oddly show reduced 
incidence at old ages (at least in humans and rats). Our model shows that this pattern may 
emerge as a result of the senescent cell theory of ageing. We also argue (although we did not 
formally model this) that accumulation of senescent cells with age might also resolve Peto’s 
paradox, e.g., the fact that cancer prevalence is not a function of species’ size and longevity. 
If senescent cells accumulate at different paces within tissues between species of different 
sizes and longevities, large and long-lived species may exhibit increased aging rates and 
consequently postponed incidence of cancers. 
This preliminary model provides a ‘proof of principle’ that trade-offs between mortality 
components can interestingly shape mortality patterns over age, and provides a first step in 
investigating these phenomena. But there are many key directions for further investigation, 
including (i) explicitly incorporating models of apoptosis and carcinogenesis (as in (Nunney 
1993, Nunney and Muir 2015)); (ii) exploring the effect of size and metabolism across the tree 
of life for developing predictions about the potential of the senescent cells theory to resolve 
Peto’s paradox (as in (Dang 2015)); (iii) incorporating more life-history parameters, including 
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fertility and extrinsic mortality into the demographic model framed here. Moreover, the 
kinetics of senescent cells accumulation with age in tissues, and how it relates to cancer 
incidence by age, is not known. We hope that further modelling of tissues dynamics will help 
generate testable predictions on these functional relationships.  
Is the senescent cells theory really a new theory of aging? In this field of work, there is a 
tendency to elevate a new finding related to senescence to the rank of an evolutionary theory. 
To us, rather than a new theory of ageing, and although this should be further discussed, this 
may be a core mechanism that fits within the broader umbrella of the Disposable Soma Theory 
(DST) (Kirkwood 1977, Kirkwood and Holliday 1979). The DST explains senescence by the 
accumulation of damage at different physiological levels due to the fact that some resources 
have to be invested in other functions, mainly to reproduction, then repair and maintenance. 
For the DST, senescence is the outcome of an evolved optimal allocation strategy under the 
constraints of physiological trade-offs. We see the senescent cells theory as a special case of 
DST where the allocation strategy concerns trade-offs between two mortality components, 
and determines the level at which organisms invest in tissue rejuvenation and slower actuarial 
senescence, at the cost of an increased risk of cancer (of course, controlling for an organism’s 
size, metabolism, phylogeny, mutation rates, efficiency in DNA repair and alternative 
immunological and anatomical mechanisms preventing cancer). Many authors have tried to 
reconcile DST with the Antagonistic Pleiotropy theory of aging (Williams 1957) via the 
existence of genes determining the allocation strategies between investing in early versus late 
fitness components (Kirkwood and Rose 1991, Partridge, et al. 1991). The senescent cells 
theory may very well be one of the rare examples for which evidence could be obtained: genes 
controlling the entrance of a cell into a senescent-state control the amount of cell division and 
will therefore control the amount of energy invested in rejuvenating tissue, thus defining the 
core processes underpinning cell dynamics over the course of an organism’s life span. 
Selection on such genes will ultimately result in a balancing of the trajectories of the two types 
of mortality.   
Considering empirical evidence for this and other theories on trade-offs between mortality 
components, we note the challenges in using aggregated population level data: in our model 
both cancer mortality and mortality by other causes will increase over most of the organism’s 
life, making trade-offs more difficult to observe than, for instance, if the decline of one cause 
were correlated to the increase of the other. The only solution to addressing this challenge is 
to derive strong theoretical expectations regarding the age-specific shape of cause-specific 
mortality in a model where trade-offs of the kind we describe here are formally implemented. 
Furthermore, because individuals die only once, trade-offs are also not observable at the 
individual level if one has only information on cause of death. To investigate such tradeoffs 
using individual data will require (i) grouping individuals according to factors likely to shape 
cause-specific mortality outcomes (for instance according to their genotypes or the 
experimental setting), or (ii) measuring biomarkers known to be good predictors of 
individuals’ future cause-specific mortality, or (iii) empirically manipulating, over the course 
of an individual’s life, the functions underpinning trade-offs between mortality components 
(for example, via the technique that allowed selective killing of senescent cells (Baker, et al. 
2011)). Finally, comparison between species requires simultaneously comparing differential 
investment in physiological functions and relating these to differential pattern of cause-
specific mortality.  
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In conclusion, trade-offs between mortality components are likely to be an important driver 
of life history evolution and yet have been strangely neglected by the field to date; possibly 
for both theoretical but also logistical reasons that we outline above. In particular, given the 
challenges to empirical investigation, we feel that such trade-offs cannot be investigated by 
evolutionary demographers acting alone, but detailed epidemiological and demographic data 
on causes of death must be allied with a nuanced understanding of the molecular, cellular, 
physiologic drivers at the individual and species level, likely requiring a profoundly 
interdisciplinary approach.  
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